---
title: "Apogee Therapeutics rises 1% to record high on AbbVie deal probe"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291847265.md"
description: "Apogee (APGE.US) rose 1.16% in after-hours to $135.05. Shares near AbbVie's $135.11 offer amid legal probe."
datetime: "2026-07-06T21:34:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291847265.md)
  - [en](https://longbridge.com/en/news/291847265.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291847265.md)
---

# Apogee Therapeutics rises 1% to record high on AbbVie deal probe

Apogee Therapeutics（APGE.US）盘后涨 1.16%，现报 135.053 美元，股价创历史新高。

AbbVie 于 06/22/2026 宣布以每股 135.11 美元现金收购 Apogee，总交易额 109 亿美元，当前股价接近收购价格。近日律师行 Monteverde & Associates 宣布对此交易展开调查。

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)

## Related News & Research

- [ABBV: Double-digit revenue growth and raised guidance driven by strong immunology and neuroscience](https://longbridge.com/en/news/294533472.md)
- [AbbVie (NYSE:ABBV) Issues Q3 2026 Earnings Guidance](https://longbridge.com/en/news/294534219.md)
- [AbbVie Reports Second-Quarter 2026 Financial Results | ABBV Stock News](https://longbridge.com/en/news/294508615.md)
- [AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates](https://longbridge.com/en/news/294508176.md)
- [AbbVie Trims FY26 Adj. EPS Outlook - Update](https://longbridge.com/en/news/294512781.md)